Baxter's vaccines, soon to be Pfizer's, help it exceed Q3 guidance; Pfenex and PATH partner up;

> Baxter's ($BAX) marketed vaccines--on their way to Pfizer ($PFE) thanks to a July deal--chipped in $21 million, or $0.04 per diluted share, in net income for Q3. Release

> Pfenex ($PFNX) and PATH have partnered up to enhance vaccine production; the two are working on an initial pilot project for two vaccine components. More

> Vaxart's tablet vaccine for H1N1 influenza generated protective immunity equivalent to an injectable in a Phase I clinical trial. Release

> The International Medica Foundation has licensed to BravoVax a rotavirus vaccine for newborns. More

> Unexpected delays from multiple manufacturers are causing postponements of flu shipments to some healthcare providers, according to distributor FFF. Release

> France's Imaxio has inked an option for a license agreement with the German Center for Cancer Research to evaluate the former's pro-immunogenic technology with a candidate vaccine targeting HPV. More

And Finally... The Vaccine & Gene Therapy Institute of Florida (VGTI Florida) has partnered with Sweden's Karolinska Institutet to fight diseases associated with aging. More (sub. req.)

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan